trending Market Intelligence /marketintelligence/en/news-insights/trending/OFcDf7kWGRKQLGZdQGSXUw2 content esgSubNav
In This List

Trillium Therapeutics cuts 40% of staff to focus on developing cancer treatment

Blog

Global Capital Markets & SPAC Activity – H1 2021

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management


Trillium Therapeutics cuts 40% of staff to focus on developing cancer treatment

Trillium Therapeutics Inc. is cutting 17 jobs as part of a restructuring to focus its resources on the development of cancer treatments.

According to the company's Oct. 22 press release, the 40% reduction in staff is effective immediately, with 26 active employees remaining. The Mississauga, Ontario-based biotechnology company is looking for a partner for further development of its STING agonist program — a treatment that enhances the immune system to fight cancer tumors.

The company also plans to cut expenses through discontinuing its discovery research activities and through operational efficiencies.